- Current report filing (8-K)
14 June 2012 - 3:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 17, 2012
Date of Report (Date of earliest event reported)
IMMUNOTECH LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
333-57514
|
|
95-4834274
|
|
|
|
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification Number)
|
|
|
|
|
|
|
116 West Stocker Street, Glendale, California
|
|
91202
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(818) 409-9091
Registrants telephone number, including area code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
|
|
[ ]
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
[ ]
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
[ ]
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
[ ]
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01. Entry into a Material Definitive Agreement.
In March 2012, Immunotech Laboratories, Inc. and collectively the Zhabilov Group, entered into a binding Release
and Settlement Agreement with Viral Genetics Inc. and collectively the Viral Group and its principals that was approved by the
court. The Settlement ends the almost 5-year-old lawsuit between the parties, dismissing all claims without admission of liability
by any party.
The Company’s HIV/AIDS technology and the Zhabilov Group’s cancer therapeutics and detection technology intellectual
property portfolio have grown considerably in these last five years. As a result, both the Company and the Zhabilov Group are now
free to pursue possible partnerships and joint ventures at a much higher level that better reflect the value of the work.
Item 9.01
Financial Statements and Exhibits
Exhibit
Number Description
99.1 Press Release
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
IMMUNOTECH LABORATORIES, INC.
|
|
Date: May 17, 2012
|
By:
|
/s/ Ara Ghanime
|
|
|
|
Ara Ghanime
|
|
|
|
President
|
|
|
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From May 2024 to Jun 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Immunotech Laborator (CE) (OTCMarkets): 0 recent articles
More Immunotech Labs New (PN) News Articles